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Interferon-gammautations are etiologic for Tricho-Dento-Osseous syndrome. To investigate the in
vivo impact of mutant DLX3 on bone development, we established transgenic (TG) mice expressing the
c.571_574delGGGG DLX-3 gene mutation (MT-DLX3) driven by a mouse 2.3 Col1A1 promoter. Micro-
computed tomographic analyses demonstrated markedly increased trabecular bone volume and bone
mineral density in femora from TG mice. In ex vivo experiments, TG mice showed enhanced differentiation
of bone marrow stromal cells to osteoblasts and increased expression levels of bone formation markers.
However, TG mice did not show enhanced dynamic bone formation rates in in vivo ﬂuorochrome double
labeling experiments. Osteoclastic differentiation capacities of bone marrow monocytes were reduced in TG
mice in the presence of osteoclastogenic factors and the numbers of TRAP(+) osteoclasts on distal
metaphyseal trabecular bone surfaces were signiﬁcantly decreased. TRACP 5b and CTX serum levels were
signiﬁcantly decreased in TG mice, while IFN-γ levels were signiﬁcantly increased. These data demonstrate
that increased levels of IFN-γ decrease osteoclast bone resorption activities, contributing to the enhanced
trabecular bone volume and mineral density in these TG mice. These data suggest a novel role for this DLX-
3 mutation in osteoclast differentiation and bone resorption.
Published by Elsevier Inc.IntroductionTricho-Dento-Osseous (TDO) syndrome is an autosomal dominant
disorder clinically characterized byabnormalities in hair, teeth, and bone
development. Alterations in osseous tissues are major phenotypic
characteristics found in TDO cases due to the DLX3 c.571_574delGGGG
mutation (NCBI reference sequence; NM_005220), suggesting an
association between this mutation and increased thickness and density
of bone (Priceet al.,1998a;Haldemanet al., 2004). TDOpatientswith this
mutation show increased bone mineral density and thickness in the
craniofacial bones, enamel hypoplasia, severe taurodontism, and unique
kinky/curly hair (Islam et al., 2005;Wright et al., 1997; Kula et al., 1996).
These patients also show increased bone mineral density in long bones
(Haldeman et al., 2004; Islam et al., 2005). Bone volume and bone
mineral density in the radius and ulna are markedly increased, while
bone marrow cavities are markedly reduced, demonstrating enhanced
trabeculation of long bones. These data demonstrate that the DLX3
c.571_574delGGGGmutation alters bonedevelopment andhomeostasis.
In vitro studies indicate that transduction of the c.571_574delGGGG
mutant-DLX3 (MT-DLX3) into C2C12 cells increases osteocalcin genenc.expression, a bone formation marker, and markedly down-regulates
desmin gene expression, a muscle cell differentiationmarker (Delmas,
1993; Nakamura et al., 1999; Choi et al., 2008). The 4 bpDLX3mutation
introduces a frameshift that changes the last C-terminal 97 amino acids
(from191 to 287) creating a novel 119 amino acid C-terminal peptide in
the mouse DLX3 cDNA, just 3′ to the homeobox binding domain. The
homeodomain region in bothhuman andmouseDLX3 genes includes a
nuclear localization signal (NLS) fromamino acid 130 to189 (Bryan and
Morasso, 2000). The deletion mutation does not alter the structure of
the homeobox domain region, the NLS region or the nuclear
translocation ability of MT-DLX3 protein. To investigate the in vivo
impact of MT-DLX3 on bone development, we have established TG
mice expressing MT-DLX3 controlled by mouse 2.3 Col1A1 promoter.
Here, we report phenotypic bone changes and reduced osteoclastic
bone resorption associated with the upregulation of IFN-γ expression
in the bone microenvironment in MT-DLX3 transgenic mice.
Materials and methods
Generation of MT-DLX3 TG mice
All experiments were performed under an NIDCR approved animal
protocol. A Bam HI restriction site was generated in the mouse 2.3
Fig. 1. (A) Schematic diagram of Col1A1 MT-DLX3 TG construct (5 kb) containing mouse
2.3 kb type I collagen promoter, 2.7 kb mouse MT-DLX3 cDNA, and Bgh poly A tail (pA).
Col1A1SS1 and AS4 primers were used for the PCR genotyping. (B) XbaI digested
chromosomal DNA from tail biopsies was used for genomic southern blot analyses.
Three TG lines (TG1, TG2, and TG3) were identiﬁed (Con: non transgenic control). The
5 kb transgene bands were detected in TG1, TG2 and TG3.
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mouse 2.3 Col1A1 promoter speciﬁc primer (5′ TAG GGA TCC CTA GAC
CCT AGA CAT GTA GAC 3′; Bam HI site underlined; starting at
nt6338755 of GenBank accession number NT_165773.2) and T7
universal primer. The PCR product was subcloned into the Bam HI
site and Not I site (multiple cloning site) of the pBS KS II vector
(Stratagene, CA). A mouse MT-DLX3 cDNA with a 4 bp deletion
mutation (Choi et al., 2008) was ampliﬁed by PCR, using a mouse DLX3
speciﬁc primer (5′GGGAGATCTCCAGCATGAGCGGCTCCTTCG3′; Bgl
II site underlined; starting at 199 bp 5′ of the mouse DLX3 cDNA
(GenBank accessionnumberNM_010055.2)) and the BghRev universal
primer. AmpliﬁedMT-DLX3 PCR productwas double-digestedwith Bgl
II and Xho I, and cloned into the pBS KSII vector containing the 2.3
Col1A1 promoter (Fig. 1A). The identity of the full length MT-DLX3
transgenic construct was conﬁrmed by sequence analysis and the
linearized DNAwas injected into the pronuclei of fertilized FVBmouse
oocytes and implanted into 12 pseudopregnant recipients. Initial
genotyping of TG mice was performed by PCR using tail biopsies from
pups and primers speciﬁc for the 2.3 Col1A1 promoter (Col1A1SS1; 5′Fig. 2.Microcomputed tomography of femora frommale TG andmale control mice. (A) Two d
d, axial view; c,f, coronal view; b,e, cubic view; yellow cylinder represents an isotropic voxe
dimensional structure of trabecular bone from 6 week- to 12 month-old male mice. (C) Quan
tissue volume (a); Tb.Th, trabecular bone thickness (b); Tb.N, trabecular bone number (
hydroxyapatite mg [HyAp/CC] (e); (p: ⁎b0.05, data represent mean±SEM).TGC TGT TCT TGGGGGACTAC 3′) and theMT-DLX3 (AS-4; 5′GGGGGT
CCT TCGTGGAGGGG 3′) starting at nt 1105 (Fig.1A). Positive founders
for the transgenewere reconﬁrmed by genomic southern blot analysis
using a 32P dCTP radio-labeled probe. TG mice were bred with wild
type mice to generate hemizygotes for the analysis of bone phenotype
changes. All mice were fed a soft diet, since defects in tooth
mineralization as seen in TDO cases were expected in both male and
female TG mice.
Radiographic and microcomputed tomography analysis
Long bones from 6 week- to 12 month-old male TG mice and sex
and age matched control littermates were analyzed with a Faxitron
MS-20 specimen radiography system for 90 s at 18 kV using X-OMAT
Kodak diagnostic ﬁlm. Femora from the mice were used for three
dimensional (3D) microcomputed tomographic (µCT) analyses (Rao
et al., 2006). Two dimensional (2D) µCT horizontal slices (thickness
10 µm) of the femur were scanned with a Scanco Viva CT40 (Scanco
Medical) and 3D images were reconstituted from 2D scan data, and
trabecular bone parameters were measured. Data for a total of 100
slices were obtained on each femur, with sampling 0.1–1.1 mm just
below the growth plate in the metaphysis. Parameters analyzed
included the ratio of trabecular bone volume per total bone volume,
trabecular thickness, trabecular number, trabecular separation, and
bone mineral density equivalent mass of hydroxyapatite in a
cylindrical area (1.0×1.0×0.5 mm) within the distal metaphyseal
area underneath the growth plate-metaphyseal junction as shown in
Fig. 2A.
Generation of a speciﬁc polyclonal antibody against MT-DLX3 protein
and western blot analyses
A MT-DLX3 speciﬁc antibody was produced against a polypeptide
sequence (C-WPATHRRHQHSGTH, amino acids 204–217) generated by
a 4 bp deletion mutation in the mouse DLX3 gene as describedimensional views of 3 month old male mice (a,b,c, control littermate; d,e,f, TG mouse; a,
l area for the evaluation of the trabecular bone morphometric parameters). (B) Three-
tiﬁcation of trabecular bone morphometric parameters. (BV/TV, bone volume per total
c); Tb.Sp, trabecular bone space (d); BMD, bone mineral density equivalent mass of
131S.J. Choi et al. / Developmental Biology 325 (2009) 129–137previously (Choi et al., 2008). Three DLX3 antibodies were used: one
speciﬁc for MT-DLX3 (MT-DLX3 Ab), one speciﬁc for WT-DLX3 (C-20,
SC-18143, Santa Cruz), and an antibody that recognizes both proteins
[6095 antibody] described previously (Choi et al., 2008). To evaluate
antibody speciﬁcity, western blot analyses were performed using cell
lysates from MC3T3E1 cells transfected with the WT-DLX3, MT-DLX3,
or empty vector (EV) and stimulated with β-glycerophosphate and
ascorbic acid for 5 days. Primary osteoblastic cell lysates from control
littermates and TG mice were used to determine the protein
expression levels of WT-DLX3, MT-DLX3, runx2, alkaline phospha-
tase-2 (ALKP-2), β-catenin, and biglycan. WT- and MT-DLX3 (6095
Ab), WT-DLX3 (C-20 Ab), MT-DLX3 (MT-DLX3 Ab), Runx2 antibody
(1:1000, sc-10758, Santa Cruz Biotechnology), ALKP-2 antibody
(1:2000, MAB1448, R&D Systems), β-catenin antibody (1:4000, SC-
7199, Santa Cruz Biotechnology), and biglycan (1:5000, LF-106, kindly
provided by Dr. Larry Fisher, NIDCR) were hybridized to membranes
followed by application of Horse Radish Peroxidase (HRP)-conjugated
secondary antibody to determine protein expression levels.
Histological and immunohistochemical analyses of long bone
To examine limb trabecular bone structure, standard histological
and immunohistochemical analyses were performed. Deparafﬁnized
and rehydrated femora and tibiae sections were incubated with the
speciﬁc primary antibodies diluted in Antibody Diluent (559148, BD
Biosciences) and incubated with HRP conjugated SuperPicture™
Polymer as secondary antibodies (DAB anti-Rabbit; 87-9263 and
DAB anti-Goat; 87-9363, Zymed Lab), followed by a DAB coloring
reaction. For the detection of WT- and MT-DLX3, slides of long bone
sectionswere incubatedwith pepsin (Digest-All, 00-3006, Zymed Lab)
at 37 °C for 10 min for antigen retrieval and primary antibody was
incubated on bone sections as follows: WT-DLX3-speciﬁc antibody
(1:20) and MT-DLX3-speciﬁc antibody (1:400). For immunoﬂuores-
cence double labeling, rhodamine labeled donkey anti-goat IgG and
ﬂuorescein labeled goat anti-rabbit IgG were incubated and epi-
ﬂuorescence signals were observed with an inverted ﬂuorescence
microscope using TRITC and FITC ﬁlters.
Primary mouse bone marrow stromal cell cultures and colony
formation assay
Primary bone marrow stromal cells were obtained from 6 week
old TG mice and control littermates as previously described
(Ehrlich et al., 2005). This cell population was used for the
determination of protein expression levels of runx2, ALKP-2, and
β-catenin as well as in vitro calcium deposition assays. Passage 3
stromal cells (2×104) were plated in 48-well plates with α-MEM
containing 10% FCS, and 80% conﬂuent cells were treated with
osteogenic media (α-MEM with 10% FCS) containing 50 mg/L
ascorbic acid, and 10 mM β-glycerophosphate (Franceschi and Lyer,
1992). At day 18, cells were stained for calcium deposition using
von Kossa staining and alizarin red S staining. Stained cells were
photographed with an inverted microscope, followed by elution of
bound alizarin red S with 10% cetylpyridinium chloride (wt/vol)
and measurement by spectrophotometry (550 nm) (Stanford et al.,
1995). Calcium accumulation was quantiﬁed by measurement of
acid-soluble calcium with the o-cresolphthalein complexone kit
(Calcium C-test kit, Waco) (Jono et al., 2000).
Real time PCR analysis
mRNA expression levels for DLX3, runx2, ALKP-2, β-catenin, and
biglycan were determined by real time PCR using ABI Taqman Gene
Expressionprimers (DLX3;Mm00438428_m1, runx2;Mm03003491_m1,
ALKP-2; Mm01187117_m1, β-catenin; Mm01350394_m1, IFN-γ;
Mm00801778_m1, GAPDH; Mm99999915_g1) and ABI 7900 HT.Fluorochrome labeling for the measurement of dynamic bone
formation rates
Double ﬂuorochrome in vivo labeling using alizarin red S and calcein
was performed as described (Sontag, 1980). Seven days after alizarin
red S (20 mg/kg) injection, 5 mg/kg of calcein (Sigma–Aldrich) was
administrated. Bone specimens were harvested after two days and
embedded inmethyl-methacrylate. Undecalciﬁed bone sections (10 µm
thickness) on glass slideswere used to examineepi-ﬂuorescence for the
double labeled signal using a ﬂuorescence microscope.
Osteoclast formation assay and osteoclast histomorphometry
Osteoclast formation assays were performed in stromal cell co-
culture and stromal cell free culture, using bone marrow monocytic
cells and spleen cells from 6 week old male mice (Suda et al., 1997;
Kadono et al., 2005). Non-adherentmonocytes (106/48well plate)were
cultured in α-MEM containing 10% FBS for 6 days in the presence of
various concentrations of PTHrP (10 to 100 ng/ml). For osteoclast
formation assays in a stromal cell-free system, isolated spleen cells
(5X103/48 well plate) were cultured in α-MEM containing 10% FBS in
the presence of 30 ng/ml of recombinant mouse Macrophage Colony
Stimulating Factor (rmM-CSF) and varying concentrations (10 to 50 ng/
ml) of Receptor Activator of NF kappa B Ligand (RANKL) for 6 days. At
day 6, Tartrate-Resistant Acidic Phosphatase (TRAP) staining was
performed and the number of TRAP positive multi-nucleated cells
(TRAP(+)MNC)were countedusing an invertedmicroscope in a blinded
manner. In selected experiments,100 ng/ml of anti-mouse interferon-γ
(IFN-γ) antibody (XMG1.2) and 20 pg/ml of IFN-γ were added on
culture plates to test the effect of IFN-γ on osteoclast formation.
To identify TRAP(+) osteoclasts on bone sections, specimens were
deparafﬁnized, rehydrated, and stained with TRAP. Osteoclasts were
identiﬁed as TRAP(+) cells adjacent to trabecular bone. The percent of
osteoclast surface per bone surface and the number of osteoclasts per
bone surface mmwere determined. All measurements were conﬁned
to the secondary spongiosa of the femur and restricted to trabecular
bone in an area between 0.5 to 1 mm distal from the bone growth
plate-metaphyseal junction.
Measurement of serum TRACP 5b, CTX, and interferon-γ levels
To determine osteoclast formation and bone resorption activity in
vivo, we measured serum Tartrate-Resistant Acid Phosphatase 5b
(TRACP 5b) (Alatalo et al., 2000) and carboxy-terminal collagen
crosslink (CTX) (Kiviranta et al., 2005) levels using the Mouse TRACP
5b ELISA kits (Immunodiagnostic Systems Inc) and the RatLaps™
ELISA kit (Nordic Bioscience Diagnostics). Serum expression levels of
human and mouse IFN-γ were measured using IFN-γ ELISA kit
(eBioscience, 88-7914-29 and 88-7916-29). All serum samples were
assayed in triplicate in two independent assays. Serum was obtained
from TDO affected (n=25) and unaffected (controls; n=15) following
informed consent and Human Subjects approval.
Statistical analysis
All statistical analysis was performed by Student's t-test (homo-
scedastic and heteroscedastic) and p values less than 0.05 were
considered as signiﬁcantly different.
Results
Generation of MT-DLX3 TG mice
Three lines of MT-DLX3 transgenic (TG) mice were conﬁrmed by
genomic southern blot analysis (Fig. 1B). TG mice were bred with wild
type mice to produce hemizygotes for phenotype analysis. TG mice
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and 14 day-oldmicewere not different, the bodyweights of bothmale
and female TG mice were signiﬁcantly reduced from 6 weeks to
12 months of age (about 30%). The body lengths of both male and
female TG mice were similar up to 12 months of age compared to
those of control littermates (data not shown). There were no
phenotypic differences between male and female TG mice and results
for male mice are reported in this manuscript.
Trabecular bone volume and density are signiﬁcantly increased in
MT-DLX3 TG mice
Faxitron radiographic analysis indicated enhanced trabecular bone
structure in the femora and tibiae of TG mice compared to those of
control littermates from 3 months of age. High-resolution µCT
analyses indicated markedly increased trabecular bone volume at
the distal metaphyseal area of the femur in TG mice compared to
control littermates (Fig. 2A); however cortical bone thickness was not
increased in these areas. TG mice have markedly increased trabecular
bone volume in the femora from 6weeks to 12months of age (Fig. 2B).
Quantiﬁcation of trabecular bone morphometry in the yellowFig. 3. Expression of WT- and MT-DLX3. (A) Western blot analyses performed using the 6095
DLX3 protein, and a MT-DLX3 speciﬁc antibody in MC3T3E1 cells transfected with empty
mRNA expression in primary osteoblasts from Transgenic (TG) compared to control (Con)
(Target)-Ct(GAPDH))(Con) (p: ⁎b0.05, data represent mean±SEM). (C) Primary osteoblasts
littermates expressing only WT-DLX3 protein (left panel). Quantiﬁcation of WT- and MT-DL
panel). (D) Immunohistochemical detection of WT- and MT-DLX3 proteins in bone sections
was detected in of osteoblasts as indicated by arrowheads and osteocytes as indicated by th
the nucleus of osteoblasts (arrow heads) and osteocytes (arrows). Higher magniﬁcation sho
serumwas used as a negative control (Pre Ab). (E) Immunoﬂuorescence double labeling dem
primary osteoblasts from TG mice (d; merge, a; phase contrast).cylindrical volume underneath the femur growth plate in three sex
and age matched specimens from 3 to 5 month old mice revealed that
the trabecular bone volume per tissue volumewas signiﬁcantly higher
in TGmice than control mice (Fig. 2Ca). While the average thickness of
the trabeculae (Fig. 2Cb) was not signiﬁcantly different, the average
number of trabeculae (Fig. 2Cc) was signiﬁcantly increased in TG mice
and the average space between trabeculae (Fig. 2Cd) was signiﬁcantly
reduced. Importantly, the bone mineral density equivalent mass of
hydroxyapatite in these yellow cylindrical areas was signiﬁcantly
increased in TG mice (Fig. 2Ce).
Expression pattern of WT-DLX3 and MT-DLX3 protein in limb of
MT-DLX3 TG mice
The speciﬁcities of the three DLX3 antibodies were demonstrated
in western blot analyses of cell lysates from differentiated MC3T3E1
cells, transfected with either empty vector, WT-DLX3 and MT-DLX3.
DLX3 6095 antibody detected both WT-DLX3 and MT-DLX3 proteins,
WT-DLX3 speciﬁc C-terminal antibody (C-20, SC-18143) detected only
WT-DLX3 protein and MT-DLX3 speciﬁc antibody detected only MT-
DLX3 protein (Fig. 3A). Primary osteoblasts from TGmice express ~2.3antibody that detects both WT- and MT-DLX3 proteins, C-20 antibody that detects WT-
vector (EV), WT-DLX3, and MT-DLX3. (B) Real time PCR analysis demonstrating DLX3
littermates. Fold increase represents the ratio of 2^-(Ct(Target)-Ct(GAPDH))(TG)/2^-(Ct
from TG mice expressing both WT- and MT-DLX3 proteins and cells from control
X3 proteins in primary osteoblasts (open bar; WT-DLX3, hatched bar; MT-DLX3) (right
from 6 week old male MT-DLX3 TG mice. WT-DLX3 protein but not MT-DLX3 protein
e arrows in control littermates. TG mice expressed both WT- and MT-DLX3 proteins in
ws localization of WT- and MT-DLX3 proteins in nucleus (inserted images). Pre-bleed
onstrating the WT-DLX3 (red) (c) and MT-DLX3 (b) proteins expressed in the nucleus of
133S.J. Choi et al. / Developmental Biology 325 (2009) 129–137times the level of total DLX3 mRNA (WT-plus MT-DLX3 mRNA)
compared to control littermates (WT-DLX3 only) (Fig. 3B). Expression
of WT- and MT-DLX3 proteins in primary osteoblasts from TG mice
was assessed by western blot analyses. Control littermates expressed
only WT-DLX3 and TG mice expressed both WT- and MT-DLX3
proteins (Fig. 3C). As previously reported (Choi et al., 2008), this
deletion mutation introduces frameshift producing a longer open
reading frame frameshift and generation of a 35 kDa MT-DLX3.
Quantiﬁcation of DLX3 protein expression levels in primary osteo-
blasts indicated that TGmice expressed endogenousWT-DLX3 protein
at similar levels with those of control littermates and expressed MT-
DLX3 protein at a slightly higher level (1.2 fold) compared to
endogenous WT-DLX3 (Fig. 3C). Immunohistochemical staining
demonstrated both WT- and MT-DLX3 proteins were expressed in
the nuclei of osteoblasts (indicated with arrow head) and osteocytes
(indicated with arrow) in bone sections from TGmice, while onlyWT-
DXL3 protein was detected in the nuclei of osteoblasts and osteocytes
of bone sections from control littermates (Fig. 3D). Immunoﬂuores-
cence double labeling demonstrated that bothWT-DLX3 protein (red)
and MT-DLX3 protein (green) were expressed in the nuclei of cultured
primary osteoblasts from TG mice (Fig. 3E). MT-DLX3 protein
expression was not detected in osteoclast precursors or in mature
osteoclasts by immunohistochemical methods in bone sections as
well as cultured osteoclasts from bone marrow and spleen cells of TG
mice (data not shown).
Effects of MT-DLX3 on osteoblastic bone formation in vitro and in vivo
To examine the osteogenic differentiation efﬁciency of bone
marrow stromal cells to osteoblasts, passage three primary bone
marrow stromal cells from TG mice and control littermates wereFig. 4. Effects of MT-DLX3 on osteoblastic bone formation in male mice. (A) Calcium dep
stromal cells from 6 week old mice. TG mice show enhanced alizarin red S and von Kossa s
formation in TG mice (right panels) (p: ⁎b0.05, data represent mean±SEM). (B) mRNA expre
the ratio of 2^-(Ct(Target)-Ct(GAPDH))(TG) versus 2^-(Ct(Target)-Ct(GAPDH))(Con) (p:⁎b0.05
catenin in primary osteoblasts by western blot analyses. (D) TG mice did not show enhanc
using alizarin red S and calcein, as indicated by white arrows (a,c,d, control; b,e,f, TG mi
bar=10 µm).differentiated into osteoblasts by treatment with osteogenic media. As
shown in Fig. 4A, calcium deposition was markedly increased in
primary stromal cells cultured for 18 days from TG mice as indicated
by alizarin red S and von Kossa staining. Quantiﬁcation of the alizarin
red S bound on the culture plates and mineralized nodules formed on
culture plates revealed that primary bone marrow stromal cells from
TG mice have increased calcium deposition capacities during
osteoblastic differentiation. We then performed real time PCR and
western blot analysis to determine whether MT-DLX3 increased the
expression of osteoblast differentiation markers in the passage three
primary osteoblasts stimulated with osteogenic media for 10 days. As
shown in Fig. 4B, mRNA expression levels of runx2, alkaline
phosphatase-2, and β-catenin were signiﬁcantly increased in primary
osteoblasts from MT-DLX3 TG mice. Western blot analyses also
demonstrated that the expression levels of bone formation markers,
runx2, ALKP-2, and β-catenin, were upregulated in primary osteoblast
from TG mice (Fig. 4C).
To examine the impact of MT-DLX3 on the dynamic in vivo bone
formation rate, we performed alizarin red S and calcein double
labeling studies on 6 week old male mice. As indicated by white
arrows in Fig. 4D lower panels, the double lines labeled by alizarin red
S and calcein on the non-decalciﬁed bone sections were not different
between TGmice and control littermates. Histomorphometric analysis
revealed that static bone formation parameters were not signiﬁcantly
different between TG and control littermates. Furthermore, the
number of single and double labeled surfaces and the distance
between the two double-labeled surfaces for the calculation of the
mineral apposition rate (MAR) were also not signiﬁcantly different.
Consequently, while osteoblast differentiation and nodule formation
rates in an ex vivo assay, were increased in TG bone marrow stromal
cells, in vivo bone formation rates were not increased in TG mice.osition was detected with alizarin red S and von Kossa staining using bone marrow
taining (left panels). Quantiﬁcation of alizarin red S and calcium revealed more nodule
ssion levels by real time PCR for runx2, ALKP-2, and β-catenin. Fold increase represent
, data represent mean±SEM). (C) Protein expression levels of runx2, ALKP-2, and β-
ed dynamic bone formation rates in in vivo ﬂuorochrome double labeling experiments
ce; a,b, low power; c,d,e,f, high power; c,e, trabecular bone; d,f, cortical bone; lower
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Since we did not see enhanced bone formation in TG mice in vivo,
we investigated the effects of MT-DLX3 on osteoclast differentiation
and bone resorption using mouse bone marrow (containing stromal
cells) and spleen cells (stromal cell free). The number of TRAP(+)Fig. 5. Effects of MT-DLX3 on osteoclastic bone resorption in 6 week old male mice. (A) Bon
TG (b,e) and control littermates (a,d) and differentiated into osteoclasts using varying conce
were not increased in cultured bone marrow cells from MT-DLX3 mice (hatched bar) com
MNC stimulated by rmMCS-F and RANKL were not increased in cultured spleen cells from
was performed on femora bone sections. TRAP(+) osteoclasts (OCL) are indicated (with ⁎ o
littermates (a,b) and TG mice (c,d)). (C) Histomorphometric analysis of osteoclast surface pe
[N.Oc/BS(mm)] (right panel) were performed in three consecutive slides from control litter
(D) Serum levels of TRACP 5b (left panel) and CTX (right panel) were signiﬁcantly decreaosteoclast-like MNC increased in a dose-dependent manner in the
cultured bonemarrow cells from control littermates in the presence of
50–100 ng/ml of PTHrP (Fig. 5A). In contrast, TRAP(+) osteoclast-like
MNC formation was not increased in the cultured bone marrow cells
from the TG mice. We performed osteoclast-like MNC formation
assays using a stromal cell free assay system to test whether the defecte marrow monocytes (BMM) (a,b) and spleen cells (d,e) were isolated from MT-DLX3
ntration of osteoclastogenic factors. The numbers of TRAP(+) MNC stimulated by PTHrP
pared to those of control littermates (open bar) (c). Similarly, the numbers of TRAP(+)
TG mice (hatched bar) (f) (p: ⁎b0.05, data represent means±SEM). (B) TRAP staining
n the surface of trabecular bone in the distal metaphyseal area of femora from control
r bone surface [Oc.S/BS (%)] (left panel) and the number of osteoclast per bone surface
mates (open bar) and TG mice (hatched bar) (p: ⁎b0.05, data represent means±SEM).
sed in TG mice.
135S.J. Choi et al. / Developmental Biology 325 (2009) 129–137in osteoclastogenesis in TG mice was due to abnormalities of stromal
cells. As shown in Fig. 5A right panel, the numbers of TRAP(+)
osteoclast-like MNC were dose dependently increased in the cultured
spleen cells from control littermates in the presence of 30 ng/ml of
rmM-CSF and varying concentrations of RANKL. However, the number
of TRAP(+) osteoclast-like MNC was not increased in cultured spleen
cells from TG mice by RANKL and M-CSF treatment.
TRAP staining was performed on the bone sections to identify
osteoclasts. The number of TRAP(+) osteoclasts in the distal metaphy-
seal area under the bone growth plate cartilage of TG mice was
markedly reduced compared to those of control littermates (Figs. 5Ba,
5Bc). To quantify TRAP(+) osteoclasts, histomorphometric analysis was
performed. TRAP(+) osteoclasts per bone surface in the distal
metaphyseal area of TG mice were signiﬁcantly reduced (Fig. 5C left
panel). Similarly, the numbers of osteoclasts per mm bone surface
were signiﬁcantly decreased inMT-DLX3 TGmice (Fig. 5C right panel).
We then examined the serum levels of TRACP 5b associated with in
vivo osteoclast formation and CTX representing the in vivo osteoclastic
bone resorption activity. The serum expression levels of TRACP 5b and
CTX were signiﬁcantly reduced in TG mice (Fig. 5D).
Expression levels of IFN-γ in serum and neutralizing effect of anti-mouse
IFN-γ antibody on osteoclast formation
To identify factor(s) responsible for the defect in osteoclastogen-
esis, gene expression proﬁling using the RT2 PCR proﬁler array
(PAMM-011,-018,-024,-025,-053,-064, Superarray Bioscience, MD)
and cDNA from bone marrow and spleen was performed. IFN-γ
mRNA expression levels were consistently up-regulated in TG mice.
Real time PCR results demonstrated that IFN-γ mRNA expression
levels were markedly increased in bone marrow cells (3.35±1.26 fold)
and spleen cells (2.36±0.86 fold) from TG mice compared to those of
control littermates. We then measured serum expression level ofFig. 6. Expression levels of IFN-γ and effect of IFN-γ on osteoclast formation. (A)
Expression levels of mouse IFN-γ measured by ELISA kit using mouse serum from TG
mice and control littermates. (B) Expression levels of human IFN-γ measured using
serum specimen from patients with TDO syndrome (n=25) and unaffected sibling
(n=15). (C) Effect of anti mouse IFN-γ antibody on osteoclast formation. Mouse bone
marrow cells from control littermate (open bar) and TG mice (hatched bar) were
stimulated with 30 ng/ml of RANKL in the presence and absence of 100 ng/ml of anti
mouse IFN−γ antibody and 20 pg/ml of IFN-γ. (p: ⁎b0.05, data represent means±SEM).mouse IFN-γ. As shown in Fig. 6A, serum IFN-γ expression levels were
signiﬁcantly increased in TG mice (about 5 fold). Furthermore human
IFN-γ expression levels were also signiﬁcantly increased in serum
from patients with TDO syndrome compared to unaffected control
individuals (7.3±6.1 versus 16.4±11 pg/ml) (Fig. 6B). To test whether
IFN-γ is responsible for decreased osteoclast formation in TGmice, we
performed osteoclast formation assays. As shown in Fig. 6C, the
number of osteoclast stimulated with 30 ng/ml of RANKL was
decreased in bone marrow culture from control littermates in the
presence of 20 pg/ml of IFN-γ, and 100 ng/ml of anti mouse IFN-γ
antibody reversed the inhibitory activity of IFN-γ. Osteoclast forma-
tion in bone marrow cells from TG mice was decreased compared to
those of control littermate in the presence of 30 ng/ml of RANKL while
treatment with 100 ng/ml of anti mouse IFN-γ antibody signiﬁcantly
increased osteoclast numbers.
Discussion
The DLX3 c.571_574delGGGG is the most common mutation that
causes TDO (Price et al., 1998a; Haldeman et al., 2004; Islam et al.,
2005; Price et al., 1998b). While affected individuals show increased
thickness and density of craniofacial and appendicular bones, it is
unknown if this arises from increased bone formation, decreased bone
resorption or a combination of both. To investigate the in vivo impact
of this 4 bp DLX3 deletion mutation on bone development, we
generated MT-DLX3 TG mice using the 2.3 Col1A1 promoter.
Since the 2.3 Col1A1 promoter is bone and tooth speciﬁc, we
evaluated DLX3 mRNA and protein expression levels using primary
osteoblasts from TG hemizygousmice. Total DLX3mRNA expression in
primary osteoblasts of TG mice was 2.3 fold greater than WT-DLX3
expression in WT-mice, indicating an expression ratio of ~1.3:1 for
MT-DLX3: WT-DXL3 in the TG mice. RT-PCR demonstrated MT-DLX3
levels were similar to those of WT-DLX3 in TG mice (data not shown).
Furthermore, expression levels of MT-DLX3 protein in cultured
primary osteoblasts were similar to WT-DLX3 protein in both TG
and control littermates. Consistent with our observation, multiple
reports (Kanatani et al., 2006; Gori et al., 2006; Schmidt et al., 2005;
Jiang et al., 2006) have demonstrated that the 2.3 Col1A1 promoter
expresses target proteins in a tissue speciﬁc pattern rather than gross
overexpression speciﬁcally in hemizygous mice.
Radiographic and microcomputed tomographic (µCT) analyses of
long bones demonstrated dramatically enhanced trabecular bone in
the distal metaphyseal area of femurs in TG mice from 6 weeks of age,
consistent with clinical observations in humans with TDO (Price et al.,
1998a; Haldeman et al., 2004; Islam et al., 2005; Wright et al., 1997;
Kula et al., 1996). While tooth eruption was not altered, TG mice
manifested an abnormal tooth phenotype, characterized by large pulp
chambers and defects in dentin mineralization (data not shown),
clinical ﬁndings also seen in TDO patients. We speculate that the
reduced body weight seen in both male and female TG mice may be a
consequence of eating stress.
Primary bone marrow stromal cells isolated from long bones of TG
mice cultured with osteogenic media displayed enhanced ALKP-2
activity and calcium deposition. Additionally, mRNA and protein
expression of runx2, ALKP-2, and β-catenin, which are major
osteoblastic differentiation and bone formation markers (Garimella
et al., 2004; Rodan and Noda, 1991), were up-regulated in primary
bonemarrow stromal cells from TGmice.While, TGmice did not show
an enhanced rate of dynamic bone formation by in vivo ﬂuorochrome
double labeling experiments, decreased osteoclast formation and
decreased osteoclastic bone resorption activity was observed. TGmice
demonstrated decreased numbers of osteoclasts on distalmetaphyseal
trabecular bone surfaces, and signiﬁcantly reduced serum levels of
TRACP 5b and CTX. We did not see differences in the expression levels
of RANKL and osteoprotegerin in western blot and real time PCR
analyses using primary osteoblasts from TG mice and control
136 S.J. Choi et al. / Developmental Biology 325 (2009) 129–137littermates (data not shown). These data suggest that the defect in
osteoclast formation and bone resorption seen inTGmicemight not be
due to abnormalities in stromal cells. Interestingly, TRAP(+) osteoclasts
were markedly reduced in the distal metaphyseal area but not in the
proximal metaphyseal area. MT-DLX3 protein was not expressed in
osteoclasts fromTGmice. These data suggest that highly localized bone
microenvironmental factors produced by bone marrow cells may be
responsible for the reduced osteoclastic bone resorption in TG mice.
Recent reports demonstrated that T lymphocytes and their products
have been recognized as key regulators of osteoclast formation
(Weitzmann and Paciﬁci, 2007; Takayanagi et al., 2000). Therefore,
we performed gene expression proﬁling using the RT2 PCR proﬁler
array (Superarray Bioscience, MD) with bone marrow and spleen
cDNA. IFN-γ mRNA expression levels were consistently up-regulated
in TG mice. IFN-γ can act as a potent osteoclastogenesis inhibitor by
interfering in the RANK–RANKL signaling pathway. IFN-γ induces
rapid degradation of the RANK adaptor protein, TRAF6 (tumor necrosis
factor receptor associated factor 6) (Takayanagi et al., 2002). We found
that mRNA expression levels of IFN-γ were signiﬁcantly increased in
bone marrow cells (3.35±1.26 fold) and spleen cells (2.36±0.86 fold)
from TG mice compared to control littermates. Serum levels of IFN-γ
were also elevated in TG mice (about 5 fold) and in serum specimens
from patients with TDO syndrome compared to unaffected family
members (greater than 2 fold increase). Furthermore, 20 pg/ml of IFN-
γ signiﬁcantly decreased the number of osteoclasts formed in bone
marrow cell culture from control littermates stimulated with 30 ng/ml
of RANKL. Addition of anti mouse IFN-γ antibody (100 ng/ml) reversed
the inhibitory effects of IFN-γ on osteoclast formation. Interestingly,
treatment of anti mouse IFN-γ antibody signiﬁcantly increased the
number of osteoclasts in bone marrow cell cultures from TG mice.
These data suggest that elevated IFN-γ expression appears to be
responsible for the defective osteoclast formation and bone resorption
in TGmice. Consistent with our results, Kamolmatyakul et al. reported
that 0.2 IU/ml (approximately 40 pg/ml) of IFN-γ markedly and
signiﬁcantly decreased osteoclast formation in vitro (Kamolmatyakul
et al., 2001). Takahashi et al. also reported that less than 1 IU/ml
(approximately 200 pg/ml) of IFN-γ dramatically decreased human
osteoclast formation (Takahashi et al. 1986).
Up-regulated IFN-γ expression levels in TG mice may also explain
the apparent discrepancy between in vivo and ex vivo results for the
effects of MT-DLX3 on osteoblast formation and osteoblastic bone
formation. Our previous report demonstrated that transduction ofMT-
DLX3 into C2C12 cells increased osteoblastic differentiation and
calcium deposition in vitro (Choi et al., 2008). Furthermore, our ex
vivo study demonstrated that the primary stromal cells from TG mice
showed enhanced osteoblast differentiation and calcium deposition.
However, TG mice did not show enhanced in vivo bone formation. Ex
vivo assays for osteoblastic bone formation using passage three
primary stromal cells from mice did not contain immune cells such
as T lymphocytes that express IFN-γ. However, the bone microenvir-
onment contains cells that express IFN-γ, which is known to act as an
inhibitory factor for osteoblastic bone formation. Although, in vitro and
ex vivo data showed enhanced osteoblast differentiation and nodule
formation, systemic modulating factors such as IFN-γmight attenuate
or compensate the effects of bone formation in vivo. In our TG mice,
increased expression levels of IFN-γ inhibit osteoblastic bone forma-
tion and decrease osteoclastic bone resorption in vivo. Smith et al.
reported that 10−10 M of IFN-γ signiﬁcantly decreased the expression
of collagenase digestible protein (CDP) and non-collagenase digestible
protein (NDP) in fetal rat bone cultures (Smith et al., 1987). Amento et
al. also reported that 0.1 IU of IFN-γmarkedly induced class II antigen
expression on adherent synovial cells (Amento et al., 1985). These data
demonstrated that IFN-γ suppressed osteoblast differentiation as well
as osteoblastic bone formation by inhibiting bone collagen synthesis.
Interestingly, we could not detect IFN-γ expression in passage three
stromal cells or differentiated osteoblasts from TG mice. We speculatethat MT-DLX3 expression by osteogenic cells must be causing changes
in cytokine/growth factor expression that induce IFN-γ production by
other cells, possibly T lymphocytes, via unknownmechanisms.We also
cannot exclude the possibilities that other locally produced autocrine/
paracrine and systemic endocrine factors, such as osteogenic growth
peptide (OGP) (Bab et al., 1992), parathyroid hormone related peptide
(PTHrP) (Karaplis and Deckelbaum, 1998), and insulin-like growth
factors (IGF) (Bab and Einhorn, 1993), which have critical roles in
osteoblastic bone formation, may have additional effects on osteo-
blastic bone formation in TG mice.
The molecular pathways controlled by MT-DLX3 in osteoblast
differentiation are unknown. We found that the mRNA and protein
expression levels of runx2were enhanced in primary osteoprogenitors
from TGmice (Figs. 4B, 4C). In contrast, Duverger et al. (2008) recently
reported that MT-DLX3 showed a dominant negative effect on WT-
DLX3 transcriptional activity in a transiently transfected cell model
system, even though co-expression of WT- and MT-DLX3 proteins
forms a complex with the homeobox binding domain element. This
condition appears to be a dramatic overexpression of MT-DLX3 that
might saturate MT-DLX3 protein and dysregulate DLX3 transcription
machinery associatedwith other co-factors and not reﬂect the biologic
conditions associated with TDO syndrome. Hassan et al., (2004, 2008)
reported that DLX3 is ubiquitously expressed in many cell types. It's
functional cell speciﬁcities are controlled by the selective association
with HOXA10, MSX2, RUNX2, and DLX5 homeodomain transcription
factors resulting in the repression, activation and attenuation of bone
speciﬁc genes transcription. These data demonstrate that MT-DLX3
with endogenousWT-DLX3 could bind the homeobox domain binding
motif of osteogenic factor genes and positively or negatively regulate
runx2 expression as well as other osteogenic genes via unknown
pathway depending on the association of co-factors.
Taken together, these ﬁndings indicate that decreased osteoclastic
bone resorption activity due to the increased IFN-γ expression by
immune cells increased trabecular bone volume and density in TGmice.
These results suggest a gain of function mutation induced change in
hematopoietic cells, either those that form osteoclasts or in those that
regulate osteoclast formation. While we do not know how MT-DLX3
inﬂuences IFN-γ expression in immune cells, skeletal homeostasis is
greatly inﬂuenced by components of the immune system (Rho et al.,
2004). Our ﬁndings are consistent with opposing intrinsic and extrinsic
effects. Although, in vitro and ex vivo data showed enhanced osteoblast
differentiation and nodule formation, systemic modulating factors such
as IFN-γ may attenuate or compensate the dramatic effects of bone
formation in vivo. Immune cell types with selective cytokine production
affect bone cell differentiation and bone homeostasis. Cells that
regulate bone turnover share a common precursor with inﬂammatory
immune cells and may restrict themselves anatomically, in part, by
utilizing a signaling network analogous to lymphocyte co-stimulation
(Walsh et al., 2006). Further study is needed to understand the role of
this DLX3 deletion mutation in immune cell responses including IFN-γ
production.
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